Figure 2 from Monitoring Circulating Tumor DNA During Surgical Treatment in Patients with Gastrointestinal Stromal Tumors

ctDNA characteristics in 32 patients diagnosed with GISTs. A, Detailed overview of tumor-specific ctDNA and clinical parameters. ctDNA status in relation to surgery is shown for each patient. Days at the bottom relates to surgical treatment. Red and black samples indicate samples being ctDNA positive and negative, respectively. Gray samples are negative samples, but with less than 50 cfDNA molecules detected. Patients with metastatic disease are shown as bold patient identification (ID). Information about Ki-67, tumor size, TKI treatment, and last known disease status is shown. NED, no evidence of disease; AWD, alive with disease; DBD, dead by disease. B, Tumor cell proliferation rates versus presence of ctDNA. Patients with at least one ctDNA-positive sample were considered positive. Data are shown in log10 scale. n = 32; *, P ≤ 0.05; Student t test on log-transformed values. C, Tumor size versus presence of ctDNA. Patients with at least one ctDNA-positive samples were considered positive. n = 32; **, P ≤ 0.01, Student t test. D, Total ctDNA levels versus presence of ctDNA in each sample. Data are shown in log10 scale. Values out of range (OOR) was in statistical calculation replaced with the value 0.39, which is the lowest detected value divided by two, n = 161. n.s., not significant, Student t test on log-transformed values. E, Type of tumor-specific mutation detected as ctDNA. Frequency of single-nucleotide variations (SNP) and indel. n = 32; **, P ≤ 0.01; Fisher exact test.